180 Life Sciences Corp., a clinical-stage biotechnology company, engages in the development of drug candidates in the areas of inflammatory diseases, fibrosis, and pain. Its product development platforms in Phase IIb/III clinical trials include Fibrosis and Anti-TNF platform, which focuses on fibrosis and anti-tumor necrosis factors; Synthetic Cannabidiol (CBD) Analogs platform, which are man-made derivatives of CBD; and a7nAChR platform, which focuses on alpha 7 nicotinic acetylcholine receptor. The company is headquartered in Menlo Park, California.
IPO Year: 2017
Exchange: NASDAQ
Website: 180lifesciences.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/15/2021 | $11.00 | Buy | Maxim Group |
Announcing Acquisition of Advanced Gaming Technology Platform, Positive Progress on Legacy CBD Formulation, and Strengthened Balance SheetPALO ALTO, CA / ACCESSWIRE / October 3, 2024 / 180 Life Sciences Corp. (NASDAQ:ATNF) (the "Company" or "180") is pleased to provide a corporate update covering several key initiatives.CORPORATE UPDATE HIGHLIGHTS:Company shifts focus and enters global iGaming market - completes a significant technology acquisitionExpected Compliance with Nasdaq Listing Rule 5550(b)(1) - Company expects to meet Nasdaq continued listing requirement which requires maintenance of stockholders' equity of at least $2.5 millionPositive Study Results on CBD Pill Forms - 180 achieve
PALO ALTO, CA / ACCESSWIRE / October 31, 2024 / 180 Life Sciences Corp. ("180" or the "Company") (NASDAQ:ATNF) today announced the retention of Mr. Vaclav Vincalek as Senior Technology Consultant. An accomplished technologist with a strong record in technical leadership and strategy, Mr. Vincalek has guided numerous software businesses in areas of team development, technology systems architecture, and stakeholder communication.Mr. Vincalek will work closely with management to oversee the onboarding of the recently acquired Gaming Technology Platform. Commencing this integration process marks a significant step forward in the Company's efforts to establish a robust online gaming infrastructur
PALO ALTO, CA / ACCESSWIRE / October 29, 2024 / 180 Life Sciences Corp. ("180" or the "Company") (NASDAQ:ATNF) today announced the appointment of Mr. Jay Goodman to its Board of Directors, effective immediately. Mr. Goodman brings over a decade of expertise in the software-as-a-service (SaaS) and iGaming industries, along with more than seven years of experience in executive leadership roles. Mr. Goodman's distinguished career includes contributions to several high-growth companies, successful IPOs, and extensive work in the Asia Pacific and Japan markets.Currently, Mr. Goodman serves as Sales Director for Asia Pacific and Japan at Docker, Inc., a position he has held since January 2024. Doc
LAS VEGAS, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Elray Resources Inc. (OTCPK:ELRA) is pleased to announce a significant milestone in the company's growth strategy. Elray has completed the sale of proprietary technology to 180 Life Sciences Corp. (NASDAQ:ATNF), a NASDAQ-listed company in exchange for preferred stock convertible into a 40% stake in ATNF and warrants to purchase 3 million shares of ATNF common stock, the conversion/exercise of which is subject to stockholder approval. The technology stack contained within Elray's technology package will assist ATNF in launching an iGaming Blockchain casino. "This strategic sale and potential future partnership are expected to enhance Elra
PALO ALTO, CA / ACCESSWIRE / October 9, 2024 / 180 Life Sciences Corp. (NASDAQ:ATNF) (the "Company" or "180"), is pleased to announce that it has received confirmation from Nasdaq that the Company has officially regained compliance with Nasdaq Listing Rule 5550(b)(1), which requires a minimum stockholders' equity of $2,500,000. With this important achievement, the Company can now fully focus on developing its newly announced iGaming business, while also continuing to advance its legacy biotechnology programs.As announced on October 3, 2024, 180 will be shifting its strategic focus towards the rapidly growing global iGaming sector. This transition represents a new chapter for the Company as i
Announcing Acquisition of Advanced Gaming Technology Platform, Positive Progress on Legacy CBD Formulation, and Strengthened Balance SheetPALO ALTO, CA / ACCESSWIRE / October 3, 2024 / 180 Life Sciences Corp. (NASDAQ:ATNF) (the "Company" or "180") is pleased to provide a corporate update covering several key initiatives.CORPORATE UPDATE HIGHLIGHTS:Company shifts focus and enters global iGaming market - completes a significant technology acquisitionExpected Compliance with Nasdaq Listing Rule 5550(b)(1) - Company expects to meet Nasdaq continued listing requirement which requires maintenance of stockholders' equity of at least $2.5 millionPositive Study Results on CBD Pill Forms - 180 achieve
PALO ALTO, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. ("180" or the "Company") is pleased to announce the appointment of Omar Jimenez as its new Chief Financial Officer, effective September 30, 2024. Mr. Jimenez, already a director of the Company, will play a key role in driving the financial strategy of the Company as it continues to grow and innovate in the pharma and biotechnology sectors. "We are excited to have Omar stepping onto our executive team," said Mr. Blair Jordan, CEO of 180. "His extensive financial expertise, combined with his forward-thinking approach, makes him the ideal CFO to guide us through this exciting chapter of growth and transformation fo
PALO ALTO, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- PALO ALTO, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ:ATNF) ("180 Life Sciences" or the "Company"), today announced topline results from a clinical pharmacology study (the "Study"), that evaluated the uptake of cannabidiol (CBD) in a solid formulation which can be delivered as a pill orally. The clinical trial in humans, performed with Prof. Avi Domb of the Hebrew University, School of Pharmacy, and with Prof. Elyad Davidson, of Hadassah Hospital, compared two solid formulations of CBD with a U.S. Food and Drug Administration (FDA) approved drug for epilepsy, Epidiolex. The purpose of the Study was to compa
PALO ALTO, Calif., July 23, 2024 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ:ATNF) ("180 Life Sciences" or the "Company"), today announced that it received notice from the Nasdaq Listing Qualifications Panel (the "Hearings Panel") of The Nasdaq Stock Market LLC ("Nasdaq") that the Hearings Panel has granted the Company's request for additional time to achieve compliance with Nasdaq's continued listing rules and demonstrate long-term compliance with the Equity Rule (defined below). Specifically, the Hearings Panel has agreed to provide the Company until September 20, 2024 to regain compliance with the Equity Rule and to allow the continued listing of the Company's common stock and w
PALO ALTO, Calif., July 02, 2024 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ:ATNF) ("180 Life Sciences" or the "Company"), today announced that it received notice from the Nasdaq Listing Qualifications Panel (the "Hearings Panel") of The Nasdaq Stock Market LLC ("Nasdaq") that the Hearings Panel has determined to grant the Company's request to continue its listing on The Nasdaq Stock Market, subject to the Company meeting certain conditions, including filing on or before July 31, 2024, a public disclosure describing the transactions undertaken by the Company to achieve compliance with Nasdaq's continued listing rules and demonstrate long-term compliance with the Equity Rule (define
PALO ALTO, Calif., March 14, 2024 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ:ATNF) ("180 Life Sciences" or the "Company"), today announced that the Company received a letter on March 13, 2024 from The Nasdaq Stock Market LLC ("Nasdaq") indicating that the Company has regained full compliance with the minimum bid price for continued listing on the Nasdaq pursuant to Nasdaq Listing Rule 5550(a)(2) ("Minimum Bid Price Requirement"). As indicated in the letter, Nasdaq determined that for 10 consecutive business days, the closing bid price of the Company's common stock was at or above $1.00 per share. Accordingly, the Company has regained compliance with the Minimum Bid Price Requirem
4 - 180 Life Sciences Corp. (0001690080) (Issuer)
S-1 - 180 Life Sciences Corp. (0001690080) (Filer)
10-Q - 180 Life Sciences Corp. (0001690080) (Filer)
DEFA14A - 180 Life Sciences Corp. (0001690080) (Filer)
8-K - 180 Life Sciences Corp. (0001690080) (Filer)
PRE 14A - 180 Life Sciences Corp. (0001690080) (Filer)
8-K - 180 Life Sciences Corp. (0001690080) (Filer)
8-K - 180 Life Sciences Corp. (0001690080) (Filer)
8-K - 180 Life Sciences Corp. (0001690080) (Filer)
8-K - 180 Life Sciences Corp. (0001690080) (Filer)
8-K - 180 Life Sciences Corp. (0001690080) (Filer)
SC 13G/A - 180 Life Sciences Corp. (0001690080) (Subject)
SC 13G - 180 Life Sciences Corp. (0001690080) (Subject)
SC 13G - 180 Life Sciences Corp. (0001690080) (Subject)
SC 13D/A - 180 Life Sciences Corp. (0001690080) (Subject)
SC 13G/A - 180 Life Sciences Corp. (0001690080) (Subject)
SC 13G/A - 180 Life Sciences Corp. (0001690080) (Subject)
SC 13G/A - 180 Life Sciences Corp. (0001690080) (Subject)
SC 13D/A - 180 Life Sciences Corp. (0001690080) (Subject)
SC 13G - 180 Life Sciences Corp. (0001690080) (Subject)
SC 13G - 180 Life Sciences Corp. (0001690080) (Subject)
3 - 180 Life Sciences Corp. (0001690080) (Issuer)
3 - 180 Life Sciences Corp. (0001690080) (Issuer)
3 - 180 Life Sciences Corp. (0001690080) (Issuer)
3 - 180 Life Sciences Corp. (0001690080) (Issuer)
4 - 180 Life Sciences Corp. (0001690080) (Issuer)
4 - 180 Life Sciences Corp. (0001690080) (Issuer)
4 - 180 Life Sciences Corp. (0001690080) (Issuer)
4 - 180 Life Sciences Corp. (0001690080) (Issuer)
4 - 180 Life Sciences Corp. (0001690080) (Issuer)
4 - 180 Life Sciences Corp. (0001690080) (Issuer)
PALO ALTO, CA / ACCESSWIRE / October 29, 2024 / 180 Life Sciences Corp. ("180" or the "Company") (NASDAQ:ATNF) today announced the appointment of Mr. Jay Goodman to its Board of Directors, effective immediately. Mr. Goodman brings over a decade of expertise in the software-as-a-service (SaaS) and iGaming industries, along with more than seven years of experience in executive leadership roles. Mr. Goodman's distinguished career includes contributions to several high-growth companies, successful IPOs, and extensive work in the Asia Pacific and Japan markets.Currently, Mr. Goodman serves as Sales Director for Asia Pacific and Japan at Docker, Inc., a position he has held since January 2024. Doc
PALO ALTO, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. ("180" or the "Company") is pleased to announce the appointment of Omar Jimenez as its new Chief Financial Officer, effective September 30, 2024. Mr. Jimenez, already a director of the Company, will play a key role in driving the financial strategy of the Company as it continues to grow and innovate in the pharma and biotechnology sectors. "We are excited to have Omar stepping onto our executive team," said Mr. Blair Jordan, CEO of 180. "His extensive financial expertise, combined with his forward-thinking approach, makes him the ideal CFO to guide us through this exciting chapter of growth and transformation fo
Pam Marrone joins as Chairwoman of the Board of Directors and Johan de Saegher as Independent Board Member Elicit Plant, an agricultural biotechnology company specialized in crops' resistance to water stress based on a phytosterol-based technology platform, announced today it has appointed Dr. Pam Marrone as Chairwoman of the Board of Directors and Dr. Johan de Saegher as Independent Board Member. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230301005582/en/Pam Marrone and Johan de Saegher join Elicit Plant's Board of Directors (Photo: Elicit Plant) Pam is a serial entrepreneur bringing over 30 years of leadership experience
PALO ALTO, Calif., Nov. 03, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ:ATNF) ("180 Life Sciences" or the "Company"), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced the appointment of Quan A. Vu to the role of Chief Operating Officer/Chief Business Officer. Mr. Vu is a highly versatile and accomplished strategy, corporate/business development, finance and operations executive with 20 years of "hands-on" biopharma experience. He is known as a consummate dealmaker with a demonstrated history of prospecting, evaluating, structuring and closing transactions th
MENLO PARK, Calif., May 28, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ:ATNF) (180 Life Sciences or the "Company"), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced that it has appointed Russell T. Ray, MBA and Teresa DeLuca MD, MBA to its Board of Directors ("Board") effective June 15, 2021. Russell Ray was formerly Managing Director and Co-Head of Global Health Care at Credit Suisse First Boston Corporation where he led a 50-person team with offices in Baltimore, Chicago, London, New York and San Francisco focused on providing corporate finance and M&A adv
Maxim Group initiated coverage of 180 Life Sciences Corp. with a rating of Buy and set a new price target of $11.00
180 Life Sciences Corp. (NASDAQ:ATNF) ("180 Life Sciences" or the "Company"), today announced that it received notice from the Nasdaq Listing Qualifications Panel (the "Hearings Panel") of The Nasdaq Stock Market LLC ("Nasdaq") that the Hearings Panel has granted the Company's request for additional time to achieve compliance with Nasdaq's continued listing rules and demonstrate long-term compliance with the Equity Rule (defined below). Specifically, the Hearings Panel has agreed to provide the Company until September 20, 2024 to regain compliance with the Equity Rule and to allow the continued listing of the Company's common stock and warrants on The Nasdaq Stock Market through such date, s
- SEC Filing
Gainers Mustang Bio (NASDAQ:MBIO) stock moved upwards by 307.9% to $0.53 during Monday's regular session. The company's market cap stands at $14.9 million. Scinai Immunotherapeutics (NASDAQ:SCNI) stock moved upwards by 62.17% to $5.66. The company's market cap stands at $3.2 million. ENDRA Life Sciences (NASDAQ:NDRA) shares increased by 32.33% to $0.14. The market value of their outstanding shares is at $2.3 million. Trxade Health (NASDAQ:MEDS) stock increased by 31.87% to $8.7. The company's market cap stands at $12.2 million. 180 Life Sciences (NASDAQ:ATNF) stock increased by 24.11% to $1.92. The company's market cap stands at $1.8 million. Mirum Pharmaceuticals (NASDAQ:MIRM) shares
Gainers Akanda (NASDAQ:AKAN) shares rose 177.7% to $0.37 during Friday's pre-market session. The company's market cap stands at $11.7 million. Scorpius Holdings (AMEX:SCPX) stock increased by 28.17% to $0.13. The market value of their outstanding shares is at $4.6 million. NovaBay Pharmaceuticals (AMEX:NBY) shares moved upwards by 27.0% to $0.15. The market value of their outstanding shares is at $5.7 million. ZimVie (NASDAQ:ZIMV) shares moved upwards by 23.61% to $20.99. The company's market cap stands at $572.7 million. Kintara Therapeutics (NASDAQ:KTRA) stock moved upwards by 17.16% to $0.17. The market value of their outstanding shares is at $6.6 million. As per the press release, Q
Gainers Lucy Scientific Discovery (NASDAQ:LSDI) shares moved upwards by 205.8% to $1.56 during Thursday's regular session. The company's market cap stands at $2.7 million. SINTX Techs (NASDAQ:SINT) shares moved upwards by 31.66% to $0.17. The company's market cap stands at $20.6 million. As per the news, the Q1 earnings report came out 3 days ago. Nanoviricides (AMEX:NNVC) stock increased by 23.56% to $2.22. The market value of their outstanding shares is at $26.1 million. The company's, Q3 earnings came out yesterday. Scorpius Holdings (AMEX:SCPX) shares moved upwards by 23.35% to $0.1. The company's market cap stands at $3.4 million. Onconetix (NASDAQ:ONCO) stock moved upwards by 23.2
On May 7, 2024, Dr. Jonathan Rothbard resigned as Chief Scientific Officer of the Company
Gainers Cyclacel Pharmaceuticals (NASDAQ:CYCC) stock moved upwards by 50.0% to $2.04 during Tuesday's pre-market session. The company's market cap stands at $2.6 million. GeneDx Hldgs (NASDAQ:WGS) shares rose 43.54% to $15.79. The company's market cap stands at $411.3 million. As per the news, the Q1 earnings report came out yesterday. BioRestorative Therapies (NASDAQ:BRTX) shares moved upwards by 16.93% to $1.45. The company's market cap stands at $9.8 million. Vaccinex (NASDAQ:VCNX) shares moved upwards by 15.72% to $6.77. The company's market cap stands at $10.7 million. Addex Therapeutics (NASDAQ:ADXN) stock moved upwards by 14.19% to $8.61. The market value of their outstanding sha
Gainers 180 Life Sciences (NASDAQ:ATNF) shares moved upwards by 7.4% to $2.04 during Tuesday's after-market session. The market value of their outstanding shares is at $1.7 million. ABVC BioPharma (NASDAQ:ABVC) shares rose 5.22% to $1.42. The company's market cap stands at $15.0 million. Medpace Hldgs (NASDAQ:MEDP) stock increased by 5.15% to $427.5. The company's market cap stands at $13.2 billion. The company's, Q1 earnings came out yesterday. Adverum Biotechnologies (NASDAQ:ADVM) stock increased by 5.0% to $11.55. The market value of their outstanding shares is at $239.7 million. Black Diamond Therapeutic (NASDAQ:BDTX) stock moved upwards by 4.99% to $5.26. The market value of their
Gainers Longeveron (NASDAQ:LGVN) stock rose 48.6% to $3.27 during Friday's after-market session. The company's market cap stands at $8.2 million. Adial Pharmaceuticals (NASDAQ:ADIL) shares increased by 11.96% to $1.31. The market value of their outstanding shares is at $2.1 million. Etao International Co (NASDAQ:ETAO) stock moved upwards by 11.11% to $2.7. The market value of their outstanding shares is at $13.8 million. 180 Life Sciences (NASDAQ:ATNF) shares rose 7.35% to $2.39. The market value of their outstanding shares is at $1.7 million. Inovio Pharmaceuticals (NASDAQ:INO) stock rose 6.99% to $12.62. The market value of their outstanding shares is at $294.9 million. Gossamer Bio
Gainers Landos Biopharma (NASDAQ:LABP) shares rose 173.9% to $21.45 during Monday's regular session. The market value of their outstanding shares is at $66.8 million. The company's, Q4 earnings came out 2 days ago. Altamira Therapeutics (NASDAQ:CYTO) stock moved upwards by 30.63% to $2.26. The market value of their outstanding shares is at $4.1 million. XTL Biopharmaceuticals (NASDAQ:XTLB) shares increased by 28.24% to $3.36. The company's market cap stands at $18.3 million. Nkarta (NASDAQ:NKTX) shares moved upwards by 23.87% to $11.05. The company's market cap stands at $542.2 million. As per the news, the Q4 earnings report came out 2 days ago. Sagimet Biosciences (NASDAQ:SGMT) stock